TITLE

Recently Approved

PUB. DATE
October 2008
SOURCE
Pharmaceutical Representative;Oct2008, Vol. 38 Issue 10, p12
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers new briefs related to U.S. Food and Drug Administration's approval on several drugs. Nplate of Amgen Inc. has been cleared to treat thrombocytopenia in splenectomized or non-splenectomized adults with chronic immune thrombocytopenic parpura. Banner Pharmacaps Inc.'s Stavzor has been approved to treat manic episodes associated with bipolar disorder. Novartis AG's Exforge has been granted as the first-line therapy for patients to achieve blood pressure goals.
ACCESSION #
34773788

 

Related Articles

  • FDA OKs Biotech Drug Copy. Investor's Business Daily // Investors Business Daily;3/9/2015, pA01 

    4 The approval of Novartis' ([STOCK[NYSE:NVS]]) Zarxio, which has the same indications as

  • FDA OKs First Biosimilar Drug, Knockoff Of Amgen's Neupogen. AMY REEVES // Investors Business Daily;3/6/2015, p00 

    The article reports on the drug approval of the U.S. Food & Drug Administration (FDA) on Zarxio from the Swiss pharmaceutical company Novartis. It states that the drug was a biosimilar of Neupogen drug from the biopharmaceutical company Amgen. It also mentions that Zarxio had a similar drug...

  • Amgen's Platelet Booster Nplate Gets FDA Nod.  // Bioworld Week;9/1/2008, Vol. 16 Issue 35, p2 

    The article reports on the approval given by the U.S. Food & Drug Administration on Amgen Inc.'s Nplate as a platelet-booster to treat chronic immune thrombocytopenic purpura (ITP). The Thousand Oaks, California-based company will also be responsible for following a risk evaluation and...

  • Pharma: Other News To Note.  // BioWorld Today;11/26/2012, Vol. 23 Issue 228, p5 

    The article reports that the U.S. Food and drug Administration (FDA) has granted Novartis AG clearance for marketing of its vaccine Flucelvax in the U.S.

  • Tasigna.  // Pharmaceutical Representative;Aug2010, Vol. 40 Issue 8, p11 

    The article reports that the Tasigna of Novartis AG, which will be used to treat rare blood cancer is approved by the Food and Drug Administration (FDA) in the U.S.

  • Zortress for organ rejection.  // Monthly Prescribing Reference;Jun2010, Vol. 26 Issue 6, pA.18 

    The article reports that the Food and Drug Administration (FDA) approved the use of everolimus tablets Zortress from Novartis AG to prevent rejection the of kidney transplant in adult patients in the U.S.

  • Novartis' Ilaris Gets Thumbs Down as Gout Treatment.  // Bioworld Week;6/27/2011, Vol. 19 Issue 26, p4 

    The article reports that the Ilaris drug from Novartis AG has not been approved by the U.S. Food and Drug Administration (FDA).

  • Novartis. Investor's Business Daily // Investors Business Daily;7/27/2015, pA02 

    The article reports on the drug approval received by medical company, Novartis from the U.S. Food and Drug Administration (FDA) for Odomzo, a new drug developed by company.

  • New indication supports pediatric use of Gleevec.  // Drug Topics;6/2/2003, Vol. 147 Issue 11, p5 

    Reports on the Food and Drug Administration's approval for the drug imatinib from Norvatis in Philadelphia, Pennsylvania. Test on the efficacy and safety of the drug; Indications of imatinib.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics